Ascentage Pharma Reports Impressive Sales Growth in 2025
Ascentage Pharma Group International, renowned for its innovative biopharmaceutical solutions, has announced a remarkable 93% year-over-year growth in sales of its flagship product, Olverembatinib. The total sales reached US$30.3 million (RMB 217.4 million) in the first half of the year, significantly driven by the broadening of coverage under the National Reimbursement Drug List (NRDL) in China.
Significant Steps in Product Development
Launch of Lisaftoclax
In a monumental step forward, Ascentage Pharma commenced commercial sales of Lisaftoclax, following its approval for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults on July 10, 2025. This launch marks a significant moment as it becomes the first Bcl-2 inhibitor granted conditional approval for CLL/SLL treatment in China.
Advancements in Clinical Trials
Progress Opposed by Challenges
The company is currently managing a robust pipeline comprising nine registrational clinical trials, three of which have successfully received clearance from both the FDA and EMA. The GLORA-4 Phase III trial is significant, targeting first-line high-risk myelodysplastic syndrome (MDS) patients, and has already begun enrollment in Europe and China.
Fostering Global Collaborations
With Dr. Dajun Yang as the guiding force, Ascentage Pharma's leadership reflects a commitment to overcoming unmet medical needs in oncology. The firm has leveraged collaborations with leading global health institutions to enrich its research and development efforts.
Financial Highlights for the Half-Year Period
Revenue for the six-month period ended June 30, 2025, amounted to US$32.6 million, compared to US$113.4 million during the same period in 2024. The decline in revenue stemmed primarily from previous high intellectual property revenues of US$93.4 million that were recorded in the prior year.
Investments Enhancing Future Prospects
Despite sales challenges, operational expenses have adjusted accordingly. There was a notable increase in the selling and distribution expenses that reached US$19.2 million, aimed at bolstering the commercialization efforts of both Olverembatinib and Lisaftoclax.
Company Leadership Changes and Strategic Vision
In a move that highlights its strategic vision, Ascentage Pharma recently appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President. These appointments reflect the company's commitment to strengthen its operational excellence and financial strategy as it continues on its path toward comprehensive global cancer care.
Future Outlook and Expectations
Looking forward, Ascentage Pharma plans to initiate a registrational Phase III clinical trial for Olverembatinib targeting newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients, demonstrating its ongoing commitment to innovative therapies. Besides, the company holds strong potential for further developments in the oncology landscape.
Frequently Asked Questions
What is the focus of Ascentage Pharma?
Ascentage Pharma primarily focuses on the discovery, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in cancer treatment.
What milestone did Lisaftoclax achieve?
Lisaftoclax became the first Bcl-2 inhibitor to receive conditional approval for the treatment of adult patients with CLL/SLL in China, marking its significance in cancer therapeutics.
What recent changes occurred in the company’s leadership?
Ascentage Pharma appointed Dr. Veet Misra as CFO and Eric Huang as Vice President, enhancing its leadership in corporate development and finance.
How has Olverembatinib performed financially in 2025?
Olverembatinib reported a sales increase of 93%, amounting to US$30.3 million in the first half of 2025, largely due to expanded NRDL coverage.
What corporate strategies does Ascentagefollow?
The company emphasizes innovative collaborations with globally respected health institutions and a robust pipeline strategy to fulfill unmet medical needs.
